Your browser version may not work well with NCBI's Web applications. More information
here...
-
Attention-deficit/hyperactivity disorder: a life-span perspective.
Pediatric Psychopharmacology Unit, Massachusetts General Hospital and Harvard School of Medicine, Boston 02114, USA.
There is increasing scientific recognition that attention-deficit/hyperactivity disorder (ADHD), a heterogeneous disorder that carries a high risk of comorbidity, continues past childhood and adolescence into adulthood in many cases and may be underidentified in girls. The etiology of ADHD is unknown, although evidence from family studies of ADHD suggests a genetic origin for some forms of this disorder. A variety of pharmacologic agents are available in treating ADHD: stimulant medications remain the first-line treatment for noncomorbid ADHD, whereas tricyclic antidepressants and bupropion are recommended for stimulant nonresponders and patients with more than one psychiatric disorder. Complex cases of ADHD, however, may require rational use of combined pharmacotherapy.
PMID: 9680048 [PubMed - indexed for MEDLINE]
-
Related Articles
-
Patient Drug Information
-
Dextroamphetamine (Dexedrine®, DextroStat®)
Dextroamphetamine is used as part of a treatment program for attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet than other people who are the same ...
-
Dextroamphetamine and Amphetamine (Adderall®)
The combination of dextroamphetamine and amphetamine is used as part of a treatment program for attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet ...
-
Methylphenidate (Concerta®, Metadate®, Methylin®, ...)
Methylphenidate is used as part of a treatment program for attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet than other people who are the same ag...
» See all 4 Drug Reports ...